Top

Published in:

01-03-2019

Mitochondrial membrane transporters and metabolic switch in heart failure

Authors: Vikas Kumar, T. R. Santhosh Kumar, C. C. Kartha

Published in: Heart Failure Reviews | Issue 2/2019

Abstract

Mitochondrial dysfunction is widely recognized as a major factor for the progression of cardiac failure. Mitochondrial uptake of metabolic substrates and their utilization for ATP synthesis, electron transport chain activity, reactive oxygen species levels, ion homeostasis, mitochondrial biogenesis, and dynamics as well as levels of reactive oxygen species in the mitochondria are key factors which regulate mitochondrial function in the normal heart. Alterations in these functions contribute to adverse outcomes in heart failure. Iron imbalance and oxidative stress are also major factors for the evolution of cardiac hypertrophy, heart failure, and aging-associated pathological changes in the heart. Mitochondrial ATP–binding cassette (ABC) transporters have a key role in regulating iron metabolism and maintenance of redox status in cells. Deficiency of mitochondrial ABC transporters is associated with an impaired mitochondrial electron transport chain complex activity, iron overload, and increased levels of reactive oxygen species, all of which can result in mitochondrial dysfunction. In this review, we discuss the role of mitochondrial ABC transporters in mitochondrial metabolism and metabolic switch, alterations in the functioning of ABC transporters in heart failure, and mitochondrial ABC transporters as possible targets for therapeutic intervention in cardiac failure.

Brown DA, Perry JB, Allen ME, Sabbah HN, Stauffer BL, Shaikh SR, Cleland JGF, Colucci WS, Butler J, Voors AA, Anker SD, Pitt B, Pieske B, Filippatos G, Greene SJ, Gheorghiade M (2017) Mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol 14(4):238–250. https://doi.org/10.1038/nrcardio.2016.203 CrossRefPubMed

O’Rourke B (2016) Metabolism: beyond the power of mitochondria. Nat Rev Cardiol 13:386–387. https://doi.org/10.1038/nrcardio.2016.95 CrossRefPubMed

Stanley WC, Recchia FA, Lopaschuk GD (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85:1093–1129. https://doi.org/10.1152/physrev.00006.2004 CrossRefPubMed

Barry WH (2004) Heart physiology from cell to circulation, 4th ed. Circulation 110:e313–e313. https://doi.org/10.1161/01.CIR.0000143724.99618.62 CrossRef

Andersson B, Blomström-Lundqvist C, Hedner T, Waagstein F (1991) Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. J Am Coll Cardiol 18(4):1059–1066. https://doi.org/10.1016/0735-1097(91)90767-4 CrossRefPubMed

Agnetti G, Kaludercic N, Kane LA, Elliott ST, Guo Y, Chakir K, Samantapudi D, Paolocci N, Tomaselli GF, Kass DA, van Eyk JE (2010) Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts. Circ Cardiovasc Genet 3:78–87. https://doi.org/10.1161/CIRCGENETICS.109.871236 CrossRefPubMed

Palmer JW, Tandler B, Hoppel CL (1985) Biochemical differences between subsarcolemmal and interfibrillar mitochondria from rat cardiac muscle: effects of procedural manipulations. Arch Biochem Biophys 236:691–702. https://doi.org/10.1016/0003-9861(85)90675-7 CrossRefPubMed

Lukyanenko V, Chikando A, Lederer WJ (2009) Mitochondria in cardiomyocyte Ca2+ signaling. Int J Biochem Cell Biol 41:1957–1971. https://doi.org/10.1016/j.biocel.2009.03.011 CrossRefPubMedPubMedCentral

Riva A, Tandler B, Loffredo F, Vazquez E, Hoppel C (2005) Structural differences in two biochemically defined populations of cardiac mitochondria. Am J Physiol Circ Physiol 289:H868–H872. https://doi.org/10.1152/ajpheart.00866.2004 CrossRef

10.

Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829–839. https://doi.org/10.1016/S0092-8674(00)81410-5 CrossRefPubMed

11.

Kelly DP, Scarpulla RC (2004) Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev 18:357–368. https://doi.org/10.1101/gad.1177604.GENES CrossRefPubMed

12.

Ventura-Clapier R, Garnier A, Veksler V (2008) Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res 79:208–217. https://doi.org/10.1093/cvr/cvn098 CrossRefPubMed

13.

Dufour CR, Wilson BJ, Huss JM, Kelly DP, Alaynick WA, Downes M, Evans RM, Blanchette M, Giguère V (2007) Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRα and γ. Cell Metab 5:345–356. https://doi.org/10.1016/j.cmet.2007.03.007 CrossRefPubMed

14.

Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, Saffitz JE, Medeiros DM, Valencik ML, McDonald JA, Kelly DP (2004) Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor γ coactivator-1α promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 94:525–533. https://doi.org/10.1161/01.RES.0000117088.36577.EB CrossRefPubMed

15.

Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP (2000) Peroxisome proliferator-activated receptor γ coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106:847–856. https://doi.org/10.1172/JCI10268 CrossRefPubMedPubMedCentral

16.

Stojanovski D, Guiard B, Kozjak-Pavlovic V, Pfanner N, Meisinger C (2007) Alternative function for the mitochondrial SAM complex in biogenesis of α-helical TOM proteins. J Cell Biol 179:881–893. https://doi.org/10.1083/jcb.200706043 CrossRefPubMedPubMedCentral

17.

Wiedemann N, Pfanner N (2017) Mitochondrial machineries for protein import and assembly. Annu Rev Biochem 86:685–714. https://doi.org/10.1146/annurev-biochem-060815-014352 CrossRefPubMed

18.

Hulbert AJ, Turner N, Hinde J, Else P, Guderley H (2006) How might you compare mitochondria from different tissues and different species? J Comp Physiol B Biochem Syst Environ Physiol 176:93–105. https://doi.org/10.1007/s00360-005-0025-z CrossRef

19.

Herbers E, Kekäläinen NJ, Hangas A et al (2018) Tissue specific differences in mitochondrial DNA maintenance and expression. Mitochondrion S1567-7249(17):30342–30342. https://doi.org/10.1016/j.mito.2018.01.004 CrossRef

20.

Sabbah HN, Sharov V, Riddle JM, Kono T, Lesch M, Goldstein S (1992) Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 24:1333–1347. https://doi.org/10.1016/0022-2828(92)93098-5 CrossRefPubMed

21.

Sabbah HN (2016) Targeting mitochondrial dysfunction in the treatment of heart failure. Expert Rev Cardiovasc Ther 14:1305–1313. https://doi.org/10.1080/14779072.2016.1249466 CrossRefPubMed

22.

Bacman SR, Williams SL, Pinto M, Peralta S, Moraes CT (2013) Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat Med 19:1111–1113. https://doi.org/10.1038/nm.3261 CrossRefPubMedPubMedCentral

23.

Wu F, Zhang J, Beard DA (2009) Experimentally observed phenomena on cardiac energetics in heart failure emerge from simulations of cardiac metabolism. Proc Natl Acad Sci U S A 106:7143–7148. https://doi.org/10.1073/pnas.0812768106 CrossRefPubMedPubMedCentral

24.

Aubert G, Vega RB, Kelly DP (2013) Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart. Biochim Biophys Acta 1833:840–847. https://doi.org/10.1016/j.bbamcr.2012.08.015 CrossRefPubMed

25.

Ventura-Clapier R, Garnier A, Veksler V (2004) Energy metabolism in heart failure. J Physiol 555:1–13. https://doi.org/10.1113/jphysiol.2003.055095 CrossRefPubMed

26.

Sarma S, Ardehali H, Gheorghiade M (2012) Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure. Heart Fail Rev 17:35–43. https://doi.org/10.1007/s10741-010-9208-0 CrossRefPubMed

27.

Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD (2011) Targeting fatty acid and carbohydrate oxidation — a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813:1333–1350. https://doi.org/10.1016/j.bbamcr.2011.01.015 CrossRefPubMed

28.

Lodish H, Berk A, Zipursky SL et al (2000) Molecular cell biology, 4th edn. York, New

29.

Chappell JB (1968) Systems used for the transport of substrates into mitochondria. Br Med Bull 24:150–157. https://doi.org/10.1093/oxfordjournals.bmb.a070618 CrossRefPubMed

30.

Wohlrab H, Greaney J (1978) Mitochondrial phosphate transport and the N-ethylmaleimide binding proteins of the inner membrane. BBA-Bioenergetics 503:425–436. https://doi.org/10.1016/0005-2728(78)90142-1 CrossRefPubMed

31.

Kaplan RS, Pedersen PL (1983) Characterization of phosphate efflux pathways in rat liver mitochondria. Biochem J 212:279–288. https://doi.org/10.1042/bj2120279 CrossRefPubMedPubMedCentral

32.

Gnoni GV, Priore P, Geelen MJH, Siculella L (2009) The mitochondrial citrate carrier: metabolic role and regulation of its activity and expression. IUBMB Life 61:987–994. https://doi.org/10.1002/iub.249 CrossRefPubMed

33.

Hayes DJ, Taylor DJ, Bore PJ, Hilton-Jones D, Arnold DL, Squier MV, Gent AE, Radda GK (1987) An unusual metabolic myopathy: a malate-aspartate shuttle defect. J Neurol Sci 82:27–39. https://doi.org/10.1016/0022-510X(87)90004-9 CrossRefPubMed

34.

Atlante A, Passarella S, Giannattasio S, Quagliariello E (1985) Fumarate permeation in rat liver mitochondria: fumarate/malate and fumarate/phosphate translocators. Biochem Biophys Res Commun 132:8–18. https://doi.org/10.1016/0006-291X(85)90981-7 CrossRefPubMed

35.

De Bari L, Atlante A, Guaragnella N et al (2002) D-Lactate transport and metabolism in rat liver mitochondria. Biochem J 365:391–403. https://doi.org/10.1042/BJ20020139 CrossRefPubMedPubMedCentral

36.

Esparza A, Gerdtzen ZP, Olivera-Nappa A, Salgado JC, Núñez MT (2015) Iron-induced reactive oxygen species mediate transporter DMT1 endocytosis and iron uptake in intestinal epithelial cells. Am J Phys Cell Phys 309:C558–C567. https://doi.org/10.1152/ajpcell.00412.2014 CrossRef

37.

Mouli S, Nanayakkara G, AlAlasmari A, Eldoumani H, Fu X, Berlin A, Lohani M, Nie B, Arnold RD, Kavazis A, Smith F, Beyers R, Denney T, Dhanasekaran M, Zhong J, Quindry J, Amin R (2015) The role of frataxin in doxorubicin mediated cardiac hypertrophy. Am J Physiol Heart Circ Physiol 309:H844–H859. https://doi.org/10.1152/ajpheart.00182.2015 CrossRefPubMed

38.

Lakhal-Littleton S, Wolna M, Carr CA, Miller JJJ, Christian HC, Ball V, Santos A, Diaz R, Biggs D, Stillion R, Holdship P, Larner F, Tyler DJ, Clarke K, Davies B, Robbins PA (2015) Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function. Proc Natl Acad Sci 112:3164–3169. https://doi.org/10.1073/pnas.1422373112 CrossRefPubMedPubMedCentral

39.

Sarkadi B, Homolya L, Szakács G, Váradi A (2006) Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86:1179–1236. https://doi.org/10.1152/physrev.00037.2005 CrossRefPubMed

40.

Solbach TF, König J, Fromm MF, Zolk O (2006) ATP-binding cassette transporters in the heart. Trends Cardiovasc Med 16:7–15. https://doi.org/10.1016/j.tcm.2005.10.001 CrossRefPubMed

41.

Zutz A, Gompf S, Schägger H, Tampé R (2009) Mitochondrial ABC proteins in health and disease. Biochim Biophys Acta Bioenerg 1787:681–690. https://doi.org/10.1016/j.bbabio.2009.02.009 CrossRef

42.

Schaedler TA, Faust B, Shintre CA et al (2015) Structures and functions of mitochondrial ABC transporters. Biochem Soc Trans 43:943–951. https://doi.org/10.1042/BST20150118 CrossRefPubMed

43.

Zhabyeyev P, Oudit GY (2017) Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure. Eur Heart J 38:373–375. https://doi.org/10.1093/eurheartj/ehw386 CrossRefPubMed

44.

Seguin A, Ward DM (2018) Mitochondrial ABC transporters and iron metabolism. J Clin Exp Pathol 8:338. https://doi.org/10.4172/2161-0681.1000338 CrossRef

45.

Zhabyeyev P, Oudit GY (2016) Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure. Eur Heart J 38:373–375. https://doi.org/10.1093/eurheartj/ehw386 CrossRefPubMedCentral

46.

Haddad S, Wang Y, Galy B, Korf-Klingebiel M, Hirsch V, Baru AM, Rostami F, Reboll MR, Heineke J, Flögel U, Groos S, Renner A, Toischer K, Zimmermann F, Engeli S, Jordan J, Bauersachs J, Hentze MW, Wollert KC, Kempf T (2016) Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. Eur Heart J 38:362–372. https://doi.org/10.1093/eurheartj/ehw333 CrossRef

47.

Kiss K, Kucsma N, Brozik A, Tusnady GE, Bergam P, van Niel G, Szakacs G (2015) Role of the N-terminal transmembrane domain in the endo-lysosomal targeting and function of the human ABCB6 protein. Biochem J 467:127–139. https://doi.org/10.1042/BJ20141085 CrossRefPubMed

48.

Helias V, Saison C, Ballif BA, Peyrard T, Takahashi J, Takahashi H, Tanaka M, Deybach JC, Puy H, le Gall M, Sureau C, Pham BN, le Pennec PY, Tani Y, Cartron JP, Arnaud L (2012) ABCB6 is dispensable for erythropoiesis and specifies the new blood group system Langereis. Nat Genet 44:170–173. https://doi.org/10.1038/ng.1069 CrossRefPubMedPubMedCentral

49.

Paterson JK, Shukla S, Black CM, Tachiwada T, Garfield S, Wincovitch S, Ernst DN, Agadir A, Li X, Ambudkar SV, Szakacs G, Akiyama SI, Gottesman MM (2007) Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane. Biochemistry 46:9443–9452. https://doi.org/10.1021/bi700015m CrossRefPubMed

50.

Krishnamurthy PC, Du G, Fukuda Y et al (2006) Identification of a mammalian mitochondrial porphyrin transporter. Nature 443:586–589. https://doi.org/10.1038/nature05125 CrossRefPubMed

51.

Mitsuhashi N, Miki T, Senbongi H, Yokoi N, Yano H, Miyazaki M, Nakajima N, Iwanaga T, Yokoyama Y, Shibata T, Seino S (2000) MTABC3, a novel mitochondrial ATP-binding cassette protein involved in iron homeostasis. J Biol Chem 275:17536–17540. https://doi.org/10.1074/jbc.275.23.17536 CrossRefPubMed

52.

Matsumoto K, Hagiya Y, Endo Y, Nakajima M, Ishizuka M, Tanaka T, Ogura SI (2015) Effects of plasma membrane ABCB6 on 5-aminolevulinic acid (ALA)-induced porphyrin accumulation in vitro: tumor cell response to hypoxia. Photodiagn Photodyn Ther 12:45–51. https://doi.org/10.1016/j.pdpdt.2014.12.008 CrossRef

53.

Fukuda Y, Cheong PL, Lynch J, Brighton C, Frase S, Kargas V, Rampersaud E, Wang Y, Sankaran VG, Yu B, Ney PA, Weiss MJ, Vogel P, Bond PJ, Ford RC, Trent RJ, Schuetz JD (2016) The severity of hereditary porphyria is modulated by the porphyrin exporter and Lan antigen ABCB6. Nat Commun 7:12353. https://doi.org/10.1038/ncomms12353 CrossRefPubMedPubMedCentral

54.

Paul VD, Lill R (2015) Biogenesis of cytosolic and nuclear iron–sulfur proteins and their role in genome stability. Biochim Biophys Acta Mol Cell Res 1853:1528–1539. https://doi.org/10.1016/j.bbamcr.2014.12.018 CrossRef

55.

Li J, Cowan JA (2015) Glutathione-coordinated [2Fe–2S] cluster: a viable physiological substrate for mitochondrial ABCB7 transport. Chem Commun 51:2253–2255. https://doi.org/10.1039/C4CC09175B CrossRef

56.

Schaedler TA, Thornton JD, Kruse I, Schwarzländer M, Meyer AJ, van Veen HW, Balk J (2014) A conserved mitochondrial ATP-binding cassette transporter exports glutathione polysulfide for cytosolic metal cofactor assembly. J Biol Chem 289:23264–23274. https://doi.org/10.1074/jbc.M114.553438 CrossRefPubMedPubMedCentral

57.

Taketani S, Kakimoto K, Ueta H et al (2003) Involvement of ABC7 in the biosynthesis of heme in erythroid cells: interaction of ABC7 with ferrochelatase. Blood 101:3274–3280. https://doi.org/10.1182/blood-2002-04-1212 CrossRefPubMed

58.

Csere P, Lill R, Kispal G (1998) Identification of a human mitochondrial ABC transporter, the functional orthologue of yeast Atm1p. FEBS Lett 441:266–270. https://doi.org/10.1016/S0014-5793(98)01560-9 CrossRefPubMed

59.

Allikmets R, Raskind WH, Hutchinson A, Schueck ND, Dean M, Koeller DM (1999) Mutation of a putative mitochondrial Iron transporter gene (ABC7) in X-Linked Sideroblastic Anemia and Ataxia (XLSA/a). Hum Mol Genet 8:743–749. https://doi.org/10.1093/hmg/8.5.743 CrossRefPubMed

60.

Kispal G, Csere P, Prohl C, Lill R (1999) The mitochondrial proteins Atm1p and Nfs1p are essential for biogenesis of cytosolic Fe/S proteins. EMBO J 18:3981–3989. https://doi.org/10.1093/emboj/18.14.3981 CrossRefPubMedPubMedCentral

61.

Pondarré C, Antiochos BB, Campagna DR, Clarke SL, Greer EL, Deck KM, McDonald A, Han AP, Medlock A, Kutok JL, Anderson SA, Eisenstein RS, Fleming MD (2006) The mitochondrial ATP-binding cassette transporter Abcb7 is essential in mice and participates in cytosolic iron–sulfur cluster biogenesis. Hum Mol Genet 15:953–964. https://doi.org/10.1093/hmg/ddl012 CrossRefPubMed

62.

Ichikawa Y, Bayeva M, Ghanefar M, Potini V, Sun L, Mutharasan RK, Wu R, Khechaduri A, Jairaj Naik T, Ardehali H (2012) Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export. Proc Natl Acad Sci 109:4152–4157. https://doi.org/10.1073/pnas.1119338109 CrossRefPubMedPubMedCentral

63.

Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Prasad SVN, Mutharasan RK, Naik TJ, Ardehali H (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124:617–630. https://doi.org/10.1172/JCI72931 CrossRefPubMedPubMedCentral

64.

Hyde BB, Liesa M, Elorza AA, Qiu W, Haigh SE, Richey L, Mikkola HK, Schlaeger TM, Shirihai OS (2012) The mitochondrial transporter ABC-me (ABCB10), a downstream target of GATA-1, is essential for erythropoiesis in vivo. Cell Death Differ 19:1117–1126. https://doi.org/10.1038/cdd.2011.195 CrossRefPubMedPubMedCentral

65.

Liesa M, Luptak I, Qin F, Hyde BB, Sahin E, Siwik DA, Zhu Z, Pimentel DR, Xu XJ, Ruderman NB, Huffman KD, Doctrow SR, Richey L, Colucci WS, Shirihai OS (2011) Mitochondrial transporter ATP binding cassette mitochondrial erythroid is a novel gene required for cardiac recovery after ischemia/reperfusion. Circulation 124(68):806–813. https://doi.org/10.1161/CIRCULATIONAHA.110.003418 CrossRefPubMedPubMedCentral

66.

Chen W, Dailey HA, Paw BH (2010) Ferrochelatase forms an oligomeric complex with mitoferrin-1 and Abcb10 for erythroid heme biosynthesis. Blood 116:628–630. https://doi.org/10.1182/blood-2009-12-259614 CrossRefPubMedPubMedCentral

67.

Chen W, Paradkar PN, Li L, Pierce EL, Langer NB, Takahashi-Makise N, Hyde BB, Shirihai OS, Ward DM, Kaplan J, Paw BH (2009) Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria. Proc Natl Acad Sci 106:16263–16268. https://doi.org/10.1073/pnas.0904519106 CrossRefPubMedPubMedCentral

68.

Liesa M, Qiu W, Shirihai OS (2012) Mitochondrial ABC transporters function: the role of ABCB10 (ABC-me) as a novel player in cellular handling of reactive oxygen species. Biochim Biophys Acta Mol Cell Res 1823(10):1945–1957. https://doi.org/10.1016/j.bbamcr.2012.07.013 CrossRef

69.

Couture L (2006) The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev 58:244–258. https://doi.org/10.1124/pr.58.2.7 CrossRefPubMed

70.

J. Patterson A, Zhang L (2010) Hypoxia and fetal heart development. Curr Mol Med 10:653–666. https://doi.org/10.2174/156652410792630643 CrossRef

71.

Puente BN, Kimura W, Muralidhar SA, Moon J, Amatruda JF, Phelps KL, Grinsfelder D, Rothermel BA, Chen R, Garcia JA, Santos CX, Thet SW, Mori E, Kinter MT, Rindler PM, Zacchigna S, Mukherjee S, Chen DJ, Mahmoud AI, Giacca M, Rabinovitch PS, Asaithamby A, Shah AM, Szweda LI, Sadek HA (2014) The oxygen rich postnatal environment induces cardiomyocyte cell cycle arrest through DNA damage response. Cell 157:565–579. https://doi.org/10.1016/j.cell.2014.03.032 CrossRefPubMedPubMedCentral

72.

Gibbs CL (1978) Cardiac energetics. Physiol Rev 58:174–254. https://doi.org/10.1152/physrev.1978.58.1.174 CrossRefPubMed

73.

Kolwicz SC, Purohit S, Tian R (2013) Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res 113:603–616. https://doi.org/10.1161/CIRCRESAHA.113.302095 CrossRefPubMed

74.

Schaper J, Meiser E, Stammler G (1985) Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts. Circ Res 56:377–391. https://doi.org/10.1161/01.RES.56.3.377 CrossRefPubMed

75.

Beer M, Seyfarth T, Sandstede J, Landschütz W, Lipke C, Köstler H, von Kienlin M, Harre K, Hahn D, Neubauer S (2002) Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 40:1267–1274. https://doi.org/10.1016/S0735-1097(02)02160-5 CrossRefPubMed

76.

Doenst T, Nguyen TD, Abel ED (2013) Cardiac metabolism in heart failure. Circ Res 113:709–724. https://doi.org/10.1161/CIRCRESAHA.113.300376 CrossRefPubMedPubMedCentral

77.

Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M, Teasuro P, Varricchio M, D’Onofrio F (1994) Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 43:174–179. https://doi.org/10.1016/0026-0495(94)90241-0 CrossRefPubMed

78.

Rimbaud S, Sanchez H, Garnier A, Fortin D, Bigard X, Veksler V, Ventura-Clapier R (2009) Stimulus specific changes of energy metabolism in hypertrophied heart. J Mol Cell Cardiol 46:952–959. https://doi.org/10.1016/j.yjmcc.2009.01.013 CrossRefPubMed

79.

Camici P, Marraccini P, Marzilli M, Lorenzoni R, Buzzigoli G, Puntoni R, Boni C, Bellina CR, Klassen GA, L'Abbate A et al (1989) Coronary hemodynamics and myocardial metabolism during and after pacing stress in normal humans. Am J Phys 257:E309–E317. https://doi.org/10.1152/ajpendo.1989.257.3.E309 CrossRef

80.

Dávila-Román VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ (2002) Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40:271–277. https://doi.org/10.1016/S0735-1097(02)01967-8 CrossRefPubMed

81.

Wallhaus TR, Taylor M, DeGrado TR et al (2001) Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 103:2441–2446. https://doi.org/10.1161/01.CIR.103.20.2441 CrossRefPubMed

82.

Pellieux C, Aasum E, Larsen TS, Montessuit C, Papageorgiou I, Pedrazzini T, Lerch R (2006) Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway. J Mol Cell Cardiol 41:459–466. https://doi.org/10.1016/j.yjmcc.2006.06.004 CrossRefPubMed

83.

Pellieux C, Montessuit C, Papageorgiou I, Lerch R (2009) Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-α. Cardiovasc Res 82:341–350. https://doi.org/10.1093/cvr/cvp004 CrossRefPubMed

84.

Nascimben L, Ingwall JS, Pauletto P, Friedrich J, Gwathmey JK, Saks V, Pessina AC, Allen PD (1996) Creatine kinase system in failing and nonfailing human myocardium. Circulation 94:1894–1901. https://doi.org/10.1161/01.CIR.94.8.1894 CrossRefPubMed

85.

Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G (1991) Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 122:795–801. https://doi.org/10.1016/0002-8703(91)90527-O CrossRefPubMed

86.

Wittels B, Spann JF (1968) Defective lipid metabolism in the failing heart. J Clin Invest 47:1787–1794. https://doi.org/10.1172/JCI105868 CrossRefPubMed

87.

Panchal AR, Stanley WC, Kerner J, Sabbah HN (1998) Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J Card Fail 4:121–126. https://doi.org/10.1016/S1071-9164(98)90252-4 CrossRefPubMed

88.

Rouslin W, Broge CW (1993) Mechanisms of ATP conservation during ischemia in slow and fast heart rate hearts. Am J Physiol 264:C209–C216. https://doi.org/10.1152/ajpcell.1993.264.1.C209 CrossRefPubMed

89.

Cannon MV, Sillje HH, Sijbesma JW, Vreeswijk-Baudoin I, Ciapaite J, van der Sluis B, van Deursen J, Silva GJ, de Windt LJ, Gustafsson JA, van der Harst P, van Gilst WH, de Boer RA (2015) Cardiac LXR protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. EMBO Mol Med 7:1229–1243. https://doi.org/10.15252/emmm.201404669 CrossRefPubMedPubMedCentral

90.

O’Donnell JM, White LT, Lewandowski ED (1999) Mitochondrial transporter responsiveness and metabolic flux homeostasis in postischemic hearts. Am J Phys 277:H866–H873. https://doi.org/10.1152/ajpheart.1999.277.3.H866 CrossRef

91.

Walther T, Tschöpe C, Sterner-Kock A et al (2007) Accelerated mitochondrial adenosine diphosphate/adenosine triphosphate transport improves hypertension-induced heart disease. Circulation 115:333–344. https://doi.org/10.1161/CIRCULATIONAHA.106.643296 CrossRefPubMed

92.

Sigauke E, Rakheja D, Kitson K, Bennett MJ (2003) Carnitine palmitoyltransferase II deficiency: a clinical, biochemical, and molecular review. Lab Investig 83:1543–1554. https://doi.org/10.1097/01.LAB.0000098428.51765.83 CrossRefPubMed

93.

Djouadi F, Bonnefont J-P, Thuillier L, Droin V, Khadom N, Munnich A, Bastin J (2003) Correction of fatty acid oxidation in carnitine palmitoyl transferase 2–deficient cultured skin fibroblasts by bezafibrate. Pediatr Res 54:446–451. https://doi.org/10.1203/01.PDR.0000083001.91588.BB CrossRefPubMed

94.

Gibb AA, Epstein PN, Uchida S, Zheng Y, McNally LA, Obal D et al (2017) Exercise-induced changes in glucose metabolism promote physiologic cardiac growth. Circulation 136:2144–2157. https://doi.org/10.1161/CIRCULATIONAHA.117.028274 CrossRefPubMedPubMedCentral

95.

Rines AK, Ardehali H (2013) Transition metals and mitochondrial metabolism in the heart. J Mol Cell Cardiol 55:50–57. https://doi.org/10.1016/j.yjmcc.2012.05.014 CrossRefPubMed

96.

Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341:1986–1995. https://doi.org/10.1056/NEJM199912233412607 CrossRefPubMed

97.

Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P (2013) Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 34:816–829. https://doi.org/10.1093/eurheartj/ehs224 CrossRefPubMed

98.

Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W, von Haehling S, Macdougall IC, Weiss G, McMurray JJV, Anker SD, Gheorghiade M, Ponikowski P (2013) Iron status in patients with chronic heart failure. Eur Heart J 34:827–834. https://doi.org/10.1093/eurheartj/ehs377 CrossRefPubMed

99.

Sukumaran A, Chang J, Han M, Mintri S, Khaw BA, Kim J (2017) Iron overload exacerbates age-associated cardiac hypertrophy in a mouse model of hemochromatosis. Sci Rep 7(5756):5756. https://doi.org/10.1038/s41598-017-05810-2 CrossRefPubMedPubMedCentral

100.

Das SK, Wang W, Zhabyeyev P, Basu R, McLean B, Fan D, Parajuli N, DesAulniers J, Patel VB, Hajjar RJ, Dyck JRB, Kassiri Z, Oudit GY (2016) Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy. Sci Rep 5:18132. https://doi.org/10.1038/srep18132 CrossRef

101.

Medeiros DM, Jiang Y, Klaahsen D, Lin D (2009) Mitochondrial and sarcoplasmic protein changes in hearts from copper-deficient rats: up-regulation of PGC-1α transcript and protein as a cause for mitochondrial biogenesis in copper deficiency. J Nutr Biochem 20:823–830. https://doi.org/10.1016/j.jnutbio.2008.08.001 CrossRefPubMed

102.

Zeng H, Saari JT, Johnson WT (2007) Copper deficiency decreases complex IV but not complex I, II, III, or V in the mitochondrial respiratory chain in rat heart. J Nutr 137:14–18. https://doi.org/10.1093/jn/137.1.14 CrossRefPubMed

103.

Johnson WT, Johnson LK (2009) Copper deficiency inhibits Ca2+-induced swelling in rat cardiac mitochondria. J Nutr Biochem 20:248–253. https://doi.org/10.1016/j.jnutbio.2008.02.009 CrossRefPubMed

104.

Li Y, Wang L, Schuschke DA, Zhou Z, Saari JT, Kang YJ (2005) Marginal dietary copper restriction induces cardiomyopathy in rats. J Nutr 135:2130–2136. https://doi.org/10.1093/jn/135.9.2130 CrossRefPubMed

105.

Jüllig M, Chen X, Hickey AJ, Crossman DJ, Xu A, Wang Y, Greenwood DR, Choong YS, Schönberger SJ, Middleditch MJ, Phillips ARJ, Cooper GJS (2007) Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)-selective chelator. Proteomics Clin Appl 1:387–399. https://doi.org/10.1002/prca.200600770 CrossRefPubMed

106.

Miller KB, Caton JS, Finley JW (2006) Manganese depresses rat heart muscle respiration. BioFactors 28:33–46. https://doi.org/10.1002/biof.5520280104 CrossRefPubMed

107.

Gunter TE, Gerstner B, Lester T, Wojtovich AP, Malecki J, Swarts SG, Brookes PS, Gavin CE, Gunter KK (2010) An analysis of the effects of Mn2+ on oxidative phosphorylation in liver, brain, and heart mitochondria using state 3 oxidation rate assays. Toxicol Appl Pharmacol 249:65–75. https://doi.org/10.1016/j.taap.2010.08.018 CrossRefPubMedPubMedCentral

108.

Van Remmen H, Williams MD, Guo Z et al (2001) Knockout mice heterozygous for Sod2 show alterations in cardiac mitochondrial function and apoptosis. Am J Physiol Circ Physiol 281:H1422–H1432. https://doi.org/10.1152/ajpheart.2001.281.3.H1422 CrossRef

109.

Shen X, Zheng S, Metreveli NS, Epstein PN (2006) Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 55:798–805. https://doi.org/10.2337/diabetes.55.03.06.db05-1039 CrossRefPubMed

110.

Au C, Benedetto A, Aschner M (2008) Manganese transport in eukaryotes: the role of DMT1. Neurotoxicology 29:569–576. https://doi.org/10.1016/j.neuro.2008.04.022 CrossRefPubMedPubMedCentral

111.

Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90:207–258. https://doi.org/10.1152/physrev.00015.2009 CrossRefPubMed

112.

Paolisso G, De Riu S, Marrazzo G et al (1991) Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 40:972–977. https://doi.org/10.1016/0026-0495(91)90075-8 CrossRefPubMed

113.

Di NP, Di GP, Gaeta MA et al (2007) Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini DʼAbruzzo Trimetazidine Trial. J Cardiovasc Pharmacol 50:585–589. https://doi.org/10.1097/FJC.0b013e31814fa9cb CrossRef

114.

Lopaschuk GD (2003) Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 93:33e–37e. https://doi.org/10.1161/01.RES.0000086964.07404.A5 CrossRef

115.

Fragasso G, Perseghin G, De Cobelli F et al (2006) Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27:942–948. https://doi.org/10.1093/eurheartj/ehi816 CrossRefPubMed

116.

Mobini R, Fu M, Jansson P-A, Bergh CH, Scharin Täng M, Waagstein F, Andersson B (2006) Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline1-receptor agonist moxonidine. Clin Sci 110:329–336. https://doi.org/10.1042/CS20050037 CrossRef

117.

Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ, for the MOXCON Investigators (2003) Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5:659–667. https://doi.org/10.1016/S1388-9842(03)00163-6 CrossRefPubMed

118.

Fragasso G (2016) Deranged cardiac metabolism and the pathogenesis of heart failure. Card Fail Rev 2:8–13. https://doi.org/10.15420/cfr.2016:5:2 CrossRefPubMedPubMedCentral

119.

Kumar V, Aneesh KA, Kshemada K et al (2017) Amalaki rasayana, a traditional Indian drug enhances cardiac mitochondrial and contractile functions and improves cardiac function in rats with hypertrophy. Sci Rep 7:8588. https://doi.org/10.1038/s41598-017-09225-x CrossRefPubMedPubMedCentral

120.

Passarella S, Atlante A, Valenti D, de Bari L (2003) The role of mitochondrial transport in energy metabolism. Mitochondrion 2:319–343. https://doi.org/10.1016/S1567-7249(03)00008-4 CrossRefPubMed

Title: Mitochondrial membrane transporters and metabolic switch in heart failure
Authors: Vikas Kumar
T. R. Santhosh Kumar
C. C. Kartha
Publication date: 01-03-2019
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 2/2019
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-018-9756-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Mitochondrial membrane transporters and metabolic switch in heart failure

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management

Left ventricular assist device recovery: does duration of mechanical support matter?

The use of hospital-based services by heart failure patients in the last year of life: a discussion paper

Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy

B-type natriuretic peptide levels and benign adiposity in obese heart failure patients

Takotsubo syndrome: a neurocardiac syndrome inside the autonomic nervous system

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page